BioAge Labs, Inc.

For the period ended Mar 31, 2026. Filed May 8, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 8, 2026

BIOA$5.78+1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

Unaudited Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share information)

Accumulated
Additional · Other · Total
Common stock · Paid-In · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	Income	Deficit	Equity
Balance, December 31, 2025	37,386,908	—	$605,189	$278	$(333,416)	$272,051
Underwritten stock offering, net of underwriting discounts and commissions, and offering expenses	6,782,050	—	123,557	—	—	123,557
Stock option exercises	217,827	—	1,715	—	—	1,715
Stock-based compensation expense	—	—	4,256	—	—	4,256
Unrealized loss on marketable securities	—	—	—	(178)	—	(178)
Foreign currency translation adjustment	—	—	—	(27)	—	(27)
Net loss	—	—	—	—	(22,253)	(22,253)
Balance, March 31, 2026	44,386,785	$—	$734,717	$73	$(355,669)	$379,121

Accumulated
Additional · Other · Total
Common stock · Paid-In · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	Income	Deficit	Equity
Balance, December 31, 2024	35,850,037	$—	$575,693	$245	$(252,811)	$323,127
Stock-based compensation expense	—	—	2,949	—	—	2,949
Unrealized gain on marketable securities	—	—	—	29	—	29
Foreign currency translation adjustment	—	—	—	(10)	—	(10)
Net loss	—	—	—	—	(12,928)	(12,928)
Balance, March 31, 2025	35,850,037	$—	$578,642	$264	$(265,739)	$313,167

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.